Gang Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gang Wu has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Jialiang Du
National Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing 102629, China; State Key Laboratory of Drug Regulatory Science, Beijing 102629, China
6 shared publicationsGangling Xu
National Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing 102629, China; State Key Laboratory of Drug Regulatory Science, Beijing 102629, China
4 shared publicationsChuanfei Yu
National Institutes for Food and Drug Control State Key Laboratory of Drug Regulatory Science NHC Key Laboratory of Research on Quality and Standardization of Biotech Products NMPA Key Laboratory for Quality Research and Evaluation of Biological Products Beijing China
3 shared publications- Chuanfei Yu
National Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Daxing District, Beijing 102629, China; State Key Laboratory of Drug Regulatory Science, Beijing 102629, China
3 shared publications Meng Li
National Institutes for Food and Drug Control, State Key Laboratory of Drug Regulatory Science, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Daxing District, Beijing, 102629, China
3 shared publications- Chuanfei Yu
15State Key Laboratory of Drug Regulatory Science, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, Beijing, China
2 shared publications
Latest Publications
- 4 June 2026
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 280, 117600
In-depth glycosylation and aspartic acid isomerization characterization of therapeutic fusion protein using electron transfer/higher-energy collision dissociation on the new hybrid high-resolution mass spectrometer
- 4 June 2026
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 280, 117600
In-depth glycosylation and aspartic acid isomerization characterization of therapeutic fusion protein using electron transfer/higher-energy collision dissociation on the new hybrid high-resolution mass spectrometer
- Open Access
Next‐Generation HER‐2 Tumor‐Targeted Delivery of the STING Agonist Immune‐Stimulating Antibody Conjugate (ISAC) Improves Anticancer Efficacy and Induces Immunological Memory
Recently, rapidly evolving STING‐based immunotherapies have offered novel therapeutic options for various cancer types. However, systemic administration of STING agonists raises safety concerns, and intratumoral injection is constrained by tumor accessibility. Herein we developed an immune‐stimulating antibody conjugate (ISAC) that links STING agonists to antibodies that target HER2‐positive tumor cells via a cleavable linker. In vivo studies demonstrated that the STING agonist ISAC is well tolerated and exhibits potent antitumor activity in syngeneic mouse tumor models. Investigations in STING‐knockout HER2‐positive tumor cells and STING‐knockout mouse models revealed that the STING pathway primarily mediates antitumor effects upon the activation of immune and tumor cells and that the activation of immune cells plays a stronger role. Additionally, our findings indicate that the STING agonist ISAC enhances both innate and adaptive antitumor immune responses, leading to sustained antitumor activity and the establishment of immune memory. These outcomes support the clinical development of the STING agonist ISACs.
Open AccessNext‐Generation HER‐2 Tumor‐Targeted Delivery of the STING Agonist Immune‐Stimulating Antibody Conjugate (ISAC) Improves Anticancer Efficacy and Induces Immunological Memory
Recently, rapidly evolving STING‐based immunotherapies have offered novel therapeutic options for various cancer types. However, systemic administration of STING agonists raises safety concerns, and intratumoral injection is constrained by tumor accessibility. Herein we developed an immune‐stimulating antibody conjugate (ISAC) that links STING agonists to antibodies that target HER2‐positive tumor cells via a cleavable linker. In vivo studies demonstrated that the STING agonist ISAC is well tolerated and exhibits potent antitumor activity in syngeneic mouse tumor models. Investigations in STING‐knockout HER2‐positive tumor cells and STING‐knockout mouse models revealed that the STING pathway primarily mediates antitumor effects upon the activation of immune and tumor cells and that the activation of immune cells plays a stronger role. Additionally, our findings indicate that the STING agonist ISAC enhances both innate and adaptive antitumor immune responses, leading to sustained antitumor activity and the establishment of immune memory. These outcomes support the clinical development of the STING agonist ISACs.
- 30 September 2024
- Published by Wiley in Electrophoresis
- Vol. 45 (21-22) , 1915-1926
Imaged Capillary Isoelectric Focusing Coupled to High‐Resolution Mass Spectrometry (icIEF‐MS) for Cysteine‐Linked Antibody–Drug Conjugate (ADC) Heterogeneity Characterization Under Native Condition
Native mass spectrometry (nMS) is a cutting‐edge technique that leverages electrospray ionization MS (ESI‐MS) to investigate large biomolecules and their complexes in solution. The goal of nMS is to retain the native structural features and interactions of the analytes during the transition to the gas phase, providing insights into their natural conformations. In biopharmaceutical development, nMS serves as a powerful tool for analyzing complex protein heterogeneity, allowing for the examination of non‐covalently bonded assemblies in a state that closely resembles their natural folded form. Herein, we present an imaged capillary isoelectric focusing–MS (icIEF–MS) workflow to characterize cysteine‐linked antibody–drug conjugate (ADC) under native conditions. Two ADCs were analyzed: a latest generation cysteine‐linked ADC polatuzumab vedotin and the first FDA‐approved cysteine‐linked ADC brentuximab vedotin. This workflow benefits from a recently developed icIEF system that is MS‐friendly and capable of directly coupling to a high‐sensitivity MS instrument. Results show that the icIEF separation is influenced by both drug payloads and the post‐translational modifications (PTMs), which are then promptly identified by MS. Overall, this native icIEF–MS method demonstrates the potential to understand and control the critical quality attributes (CQAs) that are essential for the safe and effective use of ADCs.
- 30 September 2024
- Published by Wiley in Electrophoresis
- Vol. 45 (21-22) , 1915-1926
Imaged Capillary Isoelectric Focusing Coupled to High‐Resolution Mass Spectrometry (icIEF‐MS) for Cysteine‐Linked Antibody–Drug Conjugate (ADC) Heterogeneity Characterization Under Native Condition
Native mass spectrometry (nMS) is a cutting‐edge technique that leverages electrospray ionization MS (ESI‐MS) to investigate large biomolecules and their complexes in solution. The goal of nMS is to retain the native structural features and interactions of the analytes during the transition to the gas phase, providing insights into their natural conformations. In biopharmaceutical development, nMS serves as a powerful tool for analyzing complex protein heterogeneity, allowing for the examination of non‐covalently bonded assemblies in a state that closely resembles their natural folded form. Herein, we present an imaged capillary isoelectric focusing–MS (icIEF–MS) workflow to characterize cysteine‐linked antibody–drug conjugate (ADC) under native conditions. Two ADCs were analyzed: a latest generation cysteine‐linked ADC polatuzumab vedotin and the first FDA‐approved cysteine‐linked ADC brentuximab vedotin. This workflow benefits from a recently developed icIEF system that is MS‐friendly and capable of directly coupling to a high‐sensitivity MS instrument. Results show that the icIEF separation is influenced by both drug payloads and the post‐translational modifications (PTMs), which are then promptly identified by MS. Overall, this native icIEF–MS method demonstrates the potential to understand and control the critical quality attributes (CQAs) that are essential for the safe and effective use of ADCs.
- 8 July 2024
- Published by Wiley in Electrophoresis
- Vol. 45 (19-20) , 1665-1672
Possibility of using the imaged capillary isoelectric method as a multi‐attribute method for bispecific antibodies
An imaged capillary isoelectric focusing (icIEF)‐based method was developed and validated as a multi‐attribute method for a bispecific antibody (BsAb). First, as the traditional application of the icIEF method, it serves as an identity assay and purity assay for the BsAb. Second, the method can also be used as an impurity assay for the homodimer monoclonal antibodies generated during BsAb assembly. The homodimer impurity analysis for BsAb is usually done by hydrophobic interaction chromatography methods in the industry. The icIEF method has good sensitivity (down to 4 µg/mL in a limit of quantitation) when UV fluorescence detection is used, which detects the native fluorescence of proteins. This is the first report that an icIEF method has been applied as impurity assay.
- 8 July 2024
- Published by Wiley in Electrophoresis
- Vol. 45 (19-20) , 1665-1672
Possibility of using the imaged capillary isoelectric method as a multi‐attribute method for bispecific antibodies
An imaged capillary isoelectric focusing (icIEF)‐based method was developed and validated as a multi‐attribute method for a bispecific antibody (BsAb). First, as the traditional application of the icIEF method, it serves as an identity assay and purity assay for the BsAb. Second, the method can also be used as an impurity assay for the homodimer monoclonal antibodies generated during BsAb assembly. The homodimer impurity analysis for BsAb is usually done by hydrophobic interaction chromatography methods in the industry. The icIEF method has good sensitivity (down to 4 µg/mL in a limit of quantitation) when UV fluorescence detection is used, which detects the native fluorescence of proteins. This is the first report that an icIEF method has been applied as impurity assay.
- 19 January 2023
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 95 (4) , 2548-2560
Mass Spectrometry-Based Charge Heterogeneity Characterization of Therapeutic mAbs with Imaged Capillary Isoelectric Focusing and Ion-Exchange Chromatography as Separation Techniques
Imaged capillary isoelectric focusing (icIEF) and ion-exchange chromatography (IEX) are two essential techniques that are routinely used for charge variant analysis of therapeutic monoclonal antibodies (mAbs) during their development and in quality control. These two techniques that separate mAb charge variants based on different mechanisms and IEX have been developed as front-end separation techniques for online mass spectrometry (MS) detection, which is robust for intact protein identification. Recently, an innovative, coupled icIEF-MS technology has been constructed for protein charge variant analysis in our laboratory. In this study, icIEF-MS developed and strong cation exchange (SCX)-MS were optimized for charge heterogeneity characterization of a diverse of mAbs and their results were compared based on methodological validation. It was found that icIEF-MS outperformed SCX-MS in this study by demonstrating outstanding sensitivity, low carryover effect, accurate protein identification, and higher separation resolution although SCX-MS contributed to higher analysis throughput. Ultimately, integrating our novel icIEF-HRMS analysis with the more common SCX-MS can provide a promising and comprehensive strategy for accelerating the development of complex protein therapeutics.
- 19 January 2023
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 95 (4) , 2548-2560
Mass Spectrometry-Based Charge Heterogeneity Characterization of Therapeutic mAbs with Imaged Capillary Isoelectric Focusing and Ion-Exchange Chromatography as Separation Techniques
Imaged capillary isoelectric focusing (icIEF) and ion-exchange chromatography (IEX) are two essential techniques that are routinely used for charge variant analysis of therapeutic monoclonal antibodies (mAbs) during their development and in quality control. These two techniques that separate mAb charge variants based on different mechanisms and IEX have been developed as front-end separation techniques for online mass spectrometry (MS) detection, which is robust for intact protein identification. Recently, an innovative, coupled icIEF-MS technology has been constructed for protein charge variant analysis in our laboratory. In this study, icIEF-MS developed and strong cation exchange (SCX)-MS were optimized for charge heterogeneity characterization of a diverse of mAbs and their results were compared based on methodological validation. It was found that icIEF-MS outperformed SCX-MS in this study by demonstrating outstanding sensitivity, low carryover effect, accurate protein identification, and higher separation resolution although SCX-MS contributed to higher analysis throughput. Ultimately, integrating our novel icIEF-HRMS analysis with the more common SCX-MS can provide a promising and comprehensive strategy for accelerating the development of complex protein therapeutics.
- 8 July 2021
- Published by Wiley in Electrophoresis
- Vol. 42 (19) , 1900-1913
Interlaboratory method validation of capillary electrophoresis sodium dodecyl sulfate (CE‐SDS) methodology for analysis of mAbs
Capillary electrophoresis sodium dodecyl sulfate (CE‐SDS) is an analytical method to assess the purity of proteins, commonly applied to monoclonal antibodies (mAbs) in the biopharmaceutical industry. To address the need to standardize the CE‐SDS method in the pharmaceutical industry and to enhance the confidence in method transfer between laboratories operating different commercial capillary electrophoresis (CE) instrument platforms, an interlaboratory CE‐SDS method validation was organized involving 13 laboratories in 13 companies on four different types of commercial capillary electrophoresis instruments. In the validation, a commercial mAb therapeutic was used as the sample. The validation process followed the analytical guidelines set by the ICH guidelines (International Conference for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use). The method's precision, accuracy, linearity and range, and limit of quantitation (LOQ) were validated in the study. Variations of all the parameters validated in the study passed the pre‐set criteria defined at the beginning of the study. The definition was based on previously published works and the intended application purpose of the CE‐SDS method for mAbs. The study proved that the CE‐SDS method fits its intended application purpose as a size impurity assay and size heterogeneity characterization assay for mAb therapeutic products. This study is the first time a CE‐SDS method is validated by multiple laboratories using different commercial CE instrument platforms and on a commercial mAb therapeutic. Its results will enhance the confidence of the biopharmaceutical industry to develop CE‐SDS methods and transfer CE‐SDS methods between different laboratories.
- 8 July 2021
- Published by Wiley in Electrophoresis
- Vol. 42 (19) , 1900-1913
Interlaboratory method validation of capillary electrophoresis sodium dodecyl sulfate (CE‐SDS) methodology for analysis of mAbs
Capillary electrophoresis sodium dodecyl sulfate (CE‐SDS) is an analytical method to assess the purity of proteins, commonly applied to monoclonal antibodies (mAbs) in the biopharmaceutical industry. To address the need to standardize the CE‐SDS method in the pharmaceutical industry and to enhance the confidence in method transfer between laboratories operating different commercial capillary electrophoresis (CE) instrument platforms, an interlaboratory CE‐SDS method validation was organized involving 13 laboratories in 13 companies on four different types of commercial capillary electrophoresis instruments. In the validation, a commercial mAb therapeutic was used as the sample. The validation process followed the analytical guidelines set by the ICH guidelines (International Conference for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use). The method's precision, accuracy, linearity and range, and limit of quantitation (LOQ) were validated in the study. Variations of all the parameters validated in the study passed the pre‐set criteria defined at the beginning of the study. The definition was based on previously published works and the intended application purpose of the CE‐SDS method for mAbs. The study proved that the CE‐SDS method fits its intended application purpose as a size impurity assay and size heterogeneity characterization assay for mAb therapeutic products. This study is the first time a CE‐SDS method is validated by multiple laboratories using different commercial CE instrument platforms and on a commercial mAb therapeutic. Its results will enhance the confidence of the biopharmaceutical industry to develop CE‐SDS methods and transfer CE‐SDS methods between different laboratories.
- 1 April 2021
- Published by Elsevier in International Immunopharmacology
- Vol. 93, 107418
Development of a robust bioassay of monoclonal antibodies and biosimilars against TNF-α by NF-κB-inducible lentiviral reporter gene
- 1 April 2021
- Published by Elsevier in International Immunopharmacology
- Vol. 93, 107418
Development of a robust bioassay of monoclonal antibodies and biosimilars against TNF-α by NF-κB-inducible lentiviral reporter gene